HTIC, Inc. is a University of Virginia (UVA) spin-off biotechnology company, focusing on developing novel antibody-based biologics for unmet medical needs
Licensing and Technology:
Exclusive license for hCitH3-mAb technology developed from Dr. Jianjie Ma’s lab at UVA and Dr. Yongqing Li’s lab at University of Michigan (US/63,438778)
CMC and Regulatory Path:
Strategic collaboration with a CDMO for hCitH3-mAb production in a GMP facility, aiming for IND-enabling studies to secure FDA approval
Research and Development:
Proof-of-concept studies show hCitH3-mAb enhances survival in animal models of sepsis, mitigates cytokine storms, and accelerates wound healing in diabetic mice
Partnership and Funding:
Close partnership with UVA Licensing & Ventures Group for commercialization Funding received from:
Virginia Innovation Partnership Corporation (VIPC)
UVA-LaunchPad/Diabetes Program